- Home
- YQ vs IXHL Comparison
YQ vs IXHL Comparison
Compare YQ & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | YQ | IXHL |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 49.1M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | YQ | IXHL |
|---|---|---|
| Price | $4.20 | $0.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.9K | ★ 25.4M |
| Earning Date | 12-09-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,563,434.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.26 | $0.08 |
| 52 Week High | $6.45 | $2.25 |
Technical Indicators
Market Signals| Indicator | YQ | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 57.71 |
| Support Level | $3.80 | $0.40 |
| Resistance Level | $4.33 | $0.44 |
| Average True Range (ATR) | 0.45 | 0.05 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 65.40 | 59.28 |
Price Performance
Historical ComparisonAbout YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.